HeartBeam Inc. has entered into a commercial partnership with preventive cardiology practice ClearCardio, which will serve as the medical technology company's first commercial customer and strategic investor. The agreement, structured as a Letter of Intent, outlines subscription-based commercial terms and a collaborative deployment plan for integrating HeartBeam's technology into ClearCardio's cardiac prevention programs.
The partnership centers on HeartBeam's synthesized 12-lead ECG technology, which received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software receiving clearance in December 2025. According to the company's Cleared Indications for Use available at https://www.heartbeam.com/indications, the technology is designed for portable devices that can be used wherever the patient is located. The staged rollout will enable ClearCardio patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system, which collects ECG signals from three non-coplanar directions.
This commercial agreement represents a significant milestone for HeartBeam's broader growth strategy, which includes expansion into concierge care and preventive cardiology networks. The company continues development of its 12-lead ECG patch monitor and advancement of AI-driven cardiac care initiatives. HeartBeam's platform technology is designed to deliver actionable heart intelligence that allows physicians to identify cardiac health trends and acute conditions outside traditional medical facilities.
The partnership with ClearCardio, which serves thousands of patients through heart health screening and personalized prevention programs, underscores the strategic alignment between the two organizations. ClearCardio's planned investment in HeartBeam further solidifies this relationship. The technology integration aims to transform cardiac care by enabling remote monitoring that maintains clinical-grade standards, potentially reducing the need for in-person medical visits for routine cardiac assessments.
HeartBeam holds over 20 issued patents related to its technology enablement. The company's news and updates relating to its NASDAQ listing under the ticker BEAT are available at https://ibn.fm/BEAT. This partnership represents a practical application of HeartBeam's vision to redefine cardiac health management through portable, cable-free technology that can be deployed in various care settings beyond traditional medical facilities.
